Brianna Olson, APRN
Nurse Practitioner · Dickinson, NDNPI 1932848090
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $858, 4.6 times the $186 reported in 2022. Among nurse practitioner clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$362
- AbbVie$223
- Lilly USA, LLC$182
- E.r. Squibb & Sons, L.L.C.$170
- Novartis$127
- Lundbeck LLC$119
- plus $878 from 21 others
What the payments were for
- Food & beverage$2,061100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $362 |
| AbbVie | 18 | $223 |
| Lilly USA, LLC | 16 | $182 |
| E.r. Squibb & Sons, L.L.C. | 7 | $170 |
| Novartis | 8 | $127 |
| Lundbeck LLC | 7 | $119 |
| Pfizer | 7 | $111 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $110 |
| Actelion Pharmaceuticals US, Inc. | 3 | $67 |
| Dexcom, Inc. | 4 | $66 |
| Exact Sciences | 4 | $61 |
| Medtronic | 1 | $57 |
| Boehringer Ingelheim | 4 | $54 |
| GSK | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $41 |
| Edwards Lifesciences | 1 | $33 |
| Verona Pharma, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Novo Nordisk | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Bayer | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Merck | 1 | $13 |
| Athena Bioscience, LLC | 1 | $12 |
How this compares
$2,061 in reported general payments places this provider in the 90th percentile of 455 nurse practitioner providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 331 | $272,203 |
| JardianceEmpagliflozin | 99 | $79,281 |
| XareltoRivaroxaban | 51 | $41,738 |
| Repatha SureclickEvolocumab | 30 | $19,982 |
| TrulicityDulaglutide | 12 | $18,451 |
| EntrestoSacubitril/Valsartan | 19 | $17,936 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $17,886 |
| FarxigaDapagliflozin Propanediol | 15 | $16,555 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $15,084 |
| Praluent PenAlirocumab | 13 | $13,723 |
| Metoprolol Succinate | 552 | $9,049 |
| Rosuvastatin Calcium | 426 | $6,890 |
| Digoxin | 56 | $3,838 |
| Atorvastatin Calcium | 337 | $3,508 |
| Potassium Chloride | 126 | $3,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $111 | $272,203331 claims |
| Boehringer IngelheimJardiance | $54 | $79,28199 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $18 | $34,44038 claims |
| Lilly USA, LLCTrulicity | $182 | $18,45112 claims |
| NovartisEntresto | $127 | $17,93619 claims |
| GSKTrelegy Ellipta | $49 | $15,08416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 nurse practitioner providers in North Dakota.
Other nurse practitioner in Dickinson
- Maryann GoldDickinson$4K
- Emily GreensteinFargo$271K
- Sarah MatchaFargo$17K
- Jana SuderFargo$16K
- Lisa ClairmontBismarck$15K
- Jenna KelschMinot$9K
- McKinzie NussBismarck$7K
- Nicole MorganGrand Forks$7K
- Paula MochBismarck$5K
- Trina KaiserBismarck$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.